Leflutrozole - Mereo BioPharma

Drug Profile

Leflutrozole - Mereo BioPharma

Alternative Names: BGS-649

Latest Information Update: 23 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Mereo BioPharma; Novartis
  • Class
  • Mechanism of Action Aromatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hypogonadism
  • Discontinued Endometriosis

Most Recent Events

  • 19 Mar 2018 Efficacy and adverse events data from a phase IIb trial in Hypogonadism released by Mereo BioPharma
  • 19 Mar 2018 Mereo BioPharma completes enrolment in its phase IIb extension trial for Hypogonadism in USA
  • 30 Oct 2017 Mereo BioPharma completes enrolment in its phase IIb trial for Hypogonadism in the US, Italy, Spain and the UK (NCT02730169)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top